Stockscreener 앱 받기
5.35
3.31%
-0.09
전일 마감가:
$5.44
열려 있는:
$5.58
하루 거래량:
213.17K
Relative Volume:
2.66
시가총액:
$25.92M
수익:
$46.74M
순이익/손실:
$-114.33M
주가수익비율:
-4.1473
EPS:
-1.29
순현금흐름:
$-21.04M
1주 성능:
+6.26%
1개월 성능:
-41.77%
6개월 성능:
-85.69%
1년 성능:
-82.52%
1일 변동 폭
$5.225
$6.1314
1주일 범위
$4.51
$6.1314
52주 변동 폭
$3.60
$80.50
Scilex Holding Company Stock (SCLX) Company Profile
명칭
Scilex Holding Company
전화
(650) 516-4310
주소
960 SAN ANTONIO ROAD, PALO ALTO
SCLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
5.345 | 25.92M | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
825.91 | 739.75B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.34 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
195.71 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
69.36 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
113.25 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-27 | 개시 | D. Boral Capital | Buy |
| 2024-10-16 | 개시 | Alliance Global Partners | Buy |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-16 | 개시 | B. Riley Securities | Buy |
| 2023-10-13 | 개시 | B. Riley Securities | Buy |
| 2023-10-09 | 개시 | H.C. Wainwright | Buy |
모두보기
Scilex Holding Company 주식(SCLX)의 최신 뉴스
Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - GlobeNewswire
Scilex Regains Compliance With Nasdaq Listing Rule; Shares Rise - marketscreener.com
Scilex Holding Company Regains Compliance with Nasdaq Minimum Closing Bid Price Requirement - Nasdaq
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule - GlobeNewswire
Scilex Adjusts Record Date for Preferred Stock Dividend - TipRanks
Scilex Holding Company Announces New Record Date for Preferred Stock Dividend - Nasdaq
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 202 - The Manila Times
Scilex Holding Company Announces Change in Record Date for - GlobeNewswire
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 202 - Yahoo Finance
Scilex Holding Amends Merger Agreement with Denali By Investing.com - Investing.com Canada
Scilex Holding Amends Merger Agreement with Denali - Investing.com Australia
Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024 - Seeking Alpha
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis - The Manila Times
Scilex Gets FDA Orphan Drug Label for Colchicine for Pericarditis - marketscreener.com
Scilex Gets Orphan Drug Designation for Its Version of Colchicine - marketscreener.com
Scilex Holding Company Announces FDA Has Approved Our - GlobeNewswire
[Reporter’s Notebook] Is NeuroBiogen’s tisolagiline really worth $4.5 billion? - koreabiomed.com
Scilex Holding announces 1-for-35 reverse stock split By Investing.com - Investing.com Canada
What Does the Market Think About Scilex Holding? - Benzinga
Scilex Holding announces 1-for-35 reverse stock split - Investing.com Australia
Canada approves Scilex’s migraine solution ELYXYB - Investing.com
Scilex Holding Company Announces Approval of a New Drug - GlobeNewswire
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Witho - Yahoo Finance
Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination - GlobeNewswire Inc.
Scilex’s (SCLX) Hold Rating Reiterated at D. Boral Capital - Defense World
Scilex downgraded to Hold from Buy at D. Boral Capital - Yahoo Finance
Scilex to Implement 1-for-35 Reverse Stock Split - marketscreener.com
Scilex Announces Reverse Stock Split to Meet Nasdaq Rules - TipRanks
Scilex Holding Company Announces 1-For-35 Reverse Stock Split - marketscreener.com
Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewswire
Scilex announces 1-for-35 reverse stock split to meet Nasdaq rules - Investing.com
D. Boral Capital Has Lowered Expectations for Scilex (NASDAQ:SCLX) Stock Price - Defense World
Is Scilex Holding Company (NASDAQ: SCLX) Still A Good Investment? - stocksregister.com
Scilex Holding Company (SCLX) reports earnings - qz.com
Scilex (NASDAQ:SCLX) Stock Price Up 1.8% – Here’s What Happened - Defense World
Scilex Holding Company Has Appealed Lower Court Decision to - GlobeNewswire
Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva - The Manila Times
Hogs Weakness Extending to Wednesday - The Globe and Mail
AUDNZD Finally Turning Bearish? - The Globe and Mail
Denali Capital Acquisition Pushes Merger Deadline With Extra Funding -March 12, 2025 at 04:44 am EDT - Marketscreener.com
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Scilex Announces New Record Date for Preferred Stock - TipRanks
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, - The Manila Times
Scilex Holding Company Announces Change of Record Date for Preferred Stock Dividend - Nasdaq
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, - Yahoo Finance
Scilex Holding Ends Sales Agreement with Brokers - TipRanks
Oramed Pharmaceuticals Issues Letter to Shareholders – Company Announcement - Financial Times
Scilex Holding Company (NASDAQ:SCLX) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Breakeven Is Near for Scilex Holding Company (NASDAQ:SCLX) - Yahoo Canada Finance
Scilex Holding ends sales agreement, shares details By Investing.com - Investing.com Australia
Scilex Holding Says Terminates Sales Agreement With B. Riley, Cantor Fitzgerald, H.C. Wainwright Effective March 5 - Marketscreener.com
Scilex Holding Company (SCLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.37%
자본화:
|
볼륨(24시간):